Journal
BMJ OPEN
Volume 12, Issue 12, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2022-066335
Keywords
SOCIAL MEDICINE; HEALTH ECONOMICS; PUBLIC HEALTH
Categories
Funding
- 2022 Basic Research Project of Liaoning Provincial Department of Education [LJKMR20221296]
Ask authors/readers for more resources
China has a low level of disease burden indicators compared to other countries in the Asia-Pacific region, but as a developing country and the most populous country in the world, the total number of multiple sclerosis patients is not small. As a rare disease, the treatment cost is relatively expensive, and the cost of treating complications caused by the disease is also high. The construction of the medical security system should be strengthened to reduce the burden on individuals, families, and society.
ObjectiveTo compare the burden of multiple sclerosis disease indicators in the Asia-Pacific countries, China and globally through the Global Burden of Disease 2019 (GBD2019) Database, and to analyse the changes of multiple sclerosis disease burden in China from 1990 to 2019.Study designObservational study based on the Global Burden of Disease.SettingThe relevant incidence, prevalence, death and disability-adjusted life year (DALY) rates and corresponding age-standardised rates (ASRs) and sociodemographic index (SDI) in China, globally and in Asia-Pacific countries were extracted from the GBD2019 Database to further study the age-standardised incidence, prevalence and mortality, and the relationship between DALY rate and SDI.ResultsVarious disease burden indicators of multiple sclerosis in China are at low level in the world, and the prevalence, incidence and DALY rates have slowly increased from 1990 to 2019. During this period, the age-standardised prevalence rate (ASPR) of multiple sclerosis in China showed an upward trend, while the age-standardised death rate (ASDR), age-standardised DALY rate (ASR-DALY) and age-standardised incidence rate all decreased to varying degrees, which were roughly consistent with the global amplitude changes, and all indicators are similar to most countries in the Asia-Pacific region. As the value of the SDI increases, the ASPR of multiple sclerosis was trending upward, and the ASDR was trending downward.ConclusionCompared with other countries in the Asia-Pacific region, China is in a low state of disease burden indicators. However, as a developing country and the most populous country in the world, the total number of patients is not small, and as a rare disease, the treatment cost is relatively expensive, and the treatment cost of the complications caused by the disease is not low. The construction of the medical security system should be strengthened to reduce its burden on individuals, families and society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available